The present invention relates to pharmaceutical compositions of 6-(6-hydroxymethyl-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid (3-trifluoromethyl-phenyl)-amide, to the use of 6-(6-hydroxymethyl-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid (3-trifluoromethyl-phenyl)-amide and compositions of 6-(6-hydroxymethyl-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid (3-trifluoromethyl-phenyl)-amide in therapeutic applications, especially indications with a dysregulation/overexpression of VEFG, (neo)-vascularisation and VEGF driven angiogenesis and to methods for manufacturing such compositions, the invention further relates to specific forms of 6-(6-hydroxymethyl-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid (3-trifluoromethyl-phenyl)-amide and to the manufacturing and use of such forms. The present invention also relates to a new process to produce 6-(6-hydroxymethyl-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid (3-trifluoromethyl-phenyl)-amide.
The invention relates to compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising en a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in particular tumour diseases.
US8026247B2
申请人:——
公开号:US8026247B2
公开(公告)日:2011-09-27
[EN] BICYCLIC AMIDES AS KINASE INHIBITORS<br/>[FR] AMIDES BICYCLIQUES COMME INHIBITEURS DE KINASES
申请人:NOVARTIS AG
公开号:WO2006059234A2
公开(公告)日:2006-06-08
[EN] The invention relates to compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in particular tumour diseases. [FR] L'invention a trait à des composés représentés par la formule (I) et à l'utilisation de ceux-ci pour traiter un sujet animal ou humain, à des compositions pharmaceutiques comprenant un composé représenté par la formule I et à l'utilisation d'un composé représenté par la formule I pour préparer des compositions pharmaceutiques utiles dans le traitement de maladies dépendant des protéines kinases, notamment des maladies prolifératives telles que les tumeurs.